Long-Term Follow-Up of Combination Therapy with Sintilimab and Anlotinib in Gallbladder Follicular Dendritic Cell Sarcoma: A Rare Case Report
Jieping Yan,Xue Zhang,Lili Yu,Meihua Ye,Yun Chen
DOI: https://doi.org/10.2147/ott.s449258
IF: 4
2024-04-04
OncoTargets and Therapy
Abstract:Jieping Yan, 1, 2 Xue Zhang, 3 Lili Yu, 4 Meihua Ye, 4 Yun Chen 5 1 Clinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, People's Republic of China; 2 Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, 310014, People's Republic of China; 3 Department of Pharmacy, Kunming Yan'an Hospital, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650051, People's Republic of China; 4 Department of Pathology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, People's Republic of China; 5 Cancer Center, Department of Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, People's Republic of China Correspondence: Jieping Yan, Clinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, 158 Shangtang Road, Hangzhou, 310014, People's Republic of China, Tel +86 571 85893117, Email Yun Chen, Department of Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, 158 Shangtang Road, Hangzhou, 310014, People's Republic of China, Tel +86 571 85893609, Email Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm for which a standardized treatment approach has yet to be established. The prevailing therapeutic strategy typically involves resection followed by adjuvant chemotherapy or radiation. This case report details the long-term follow-up of a 59-year-old Chinese male diagnosed with gallbladder FDCS and liver metastases. The patient received a combination therapy of sintilimab and anlotinib, resulting in a substantial partial response (PR) lasting for a noteworthy duration of 30 months. Notably, this is the first documented instance of gallbladder FDCS with liver metastases being treated with PD-1 antibody and antiangiogenic agents as first-line therapy. These findings suggest that this treatment regimen may offer a potential therapeutic option for patients with gallbladder FDCS and liver metastases, with a duration of PR lasting up to 30 months. Keywords: gallbladder follicular dendritic cell sarcoma, long-term follow-up, PD-1 antibody, antiangiogenic agents, first-line therapy, partial response Follicular dendritic cell sarcoma (FDCS) is an exceedingly uncommon malignant cancer that was classified as a neoplasm of histiocytic and dendritic cells. The crude incidence rate for FDCS is 1 case per 200,000 individuals annually. 1 Predominantly, FDCS manifests in extranodal sites (79.4%), with lymph nodes being implicated in only approximately 15% of cases. 2 The malignancy commonly affects extranodal sites such as the spleen, liver, gastrointestinal tract, skin, lungs, mediastinum and soft tissues. 3–7 The occurrence of extra-nodal origin in the gallbladder is exceedingly uncommon, with no reported cases thus far. Due to the rarity of this malignant neoplasm, there is presently no established standard treatment for instances of inoperable and metastatic FDCS, prompting the utilization of alternative therapies, typically encompassing comprehensive approaches involving radiotherapy and chemotherapy. Nevertheless, these interventions are primarily palliative in nature and have demonstrated limited efficacy in attaining favorable treatment outcomes. The coadministration of PD-1 antibody and antiangiogenic therapy has demonstrated favorable outcomes in the regression of tumors across diverse solid malignancies, such as hepatocellular carcinoma, lung carcinoma and renal cell cancer. 8–10 Nonetheless, there is a dearth of case reports documenting extended progression-free survival (PFS) in patients with gallbladder FDCS who underwent treatment with PD-1 antibody and antiangiogenic agents. In this study, we present a case of gallbladder FDCS accompanied with liver metastases, wherein the patient was administered a first-line treatment comprising sintilimab in conjunction with anlotinib. The aforementioned patient exhibited a 30-month PR, thereby substantiating the effectiveness of this therapeutic intervention for gallbladder FDCS and underscoring potential therapeutic alternatives. A 59-year-old Chinese male was admitted to Zhejiang Provincial People's Hospital due to recurrent paroxysmal upper abdominal pain persisting for one month on December 31, 2020. The patient had a medical history of hypertension spanning over five years, which was effectively managed through regular administration of amlodipine besylate. The admissions examination revealed the lack of yellow -Abstract Truncated-
oncology,biotechnology & applied microbiology